Cassava Sciences, Inc.

NasdaqCM:SAVA 주식 보고서

시가총액: US$206.6m

Cassava Sciences 관리

관리 기준 확인 3/4

Cassava Sciences CEO는 Rick Barry, Sep2024 에 임명되었습니다 의 임기는 1년 미만입니다. 는 $ 2.02M 가치에 해당하는 회사 주식의 0.98% 직접 소유합니다. 2.02M. 경영진과 이사회의 평균 재임 기간은 각각 2 년과 6.8 년입니다.

주요 정보

Rick Barry

최고 경영자

US$546.2k

총 보상

CEO 급여 비율n/a
CEO 임기less than a year
CEO 소유권1.0%
경영진 평균 재임 기간2yrs
이사회 평균 재임 기간6.8yrs

최근 관리 업데이트

Recent updates

Cassava Q3 Earnings Review: It Feels Like The End May Be Nigh

Nov 07

Cassava Sciences: Turning The Corner Into A Brick Wall

Jul 24

Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

Oct 17
Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

Jul 04
We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate

Mar 05
We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate

Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

Nov 19
Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

Cassava Sciences begins extension study of Alzheimer's drug simufilam

Oct 13

Cassava Sciences Stock: Huge Returns Or Catastrophic Losses

Sep 29

Cassava Sciences: Trying To Manage Expectations

Sep 21

Cassava Sciences reaches over five-month high on rising volumes

Sep 09

Cassava Sciences Looks As Good Of A Purchase As Ever

Sep 03

Cassava Sciences stock jumps 10% after director buys $860K shares

Aug 26

Cassava Sciences rally continues as stock up 39%

Aug 17

Cassava's Simufilam And Acetylcholinesterase Inhibitors: Similar Results

Aug 11

Cassava Sciences GAAP EPS of -$0.48 misses by $0.06

Aug 03

We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

Aug 03
We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug

Jul 27

Cassava Sciences And Alzheimer's Disease: A Precipitious Path

Jun 10

Cassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear Debate

May 31

Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait

Apr 19
Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait

3 Key Points To Remember About Cassava Sciences

Apr 07

Retractions Of A Key Collaborator's Papers Set Up A Big April For Cassava Sciences

Mar 31

Cassava Sciences: Why The Stock Is Rangebound

Feb 28

The FDA Deals Another Blow To Cassava Sciences' Bears

Feb 11

Cassava Sciences, Inc.: Recent Trading Activity Presents An Opportunity

Feb 02

INmune Bio, The Biotech In My Stable For After Cassava Sciences

Jan 17

Cassava Sciences, Inc. - The Short Squeeze Has Started

Jan 06

Cassava Sciences, Inc. - A Rational Expectation If All Goes Well With Simufilam

Dec 30

Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth

Dec 28
Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth

Cassava Sciences Stock: Here We Go Again

Dec 21

Cassava Sciences Teaches Us 4 Lessons To Find The Next Big Thing

Dec 02

CEO

Rick Barry (65 yo)

less than a year

테뉴어

US$546,155

보상

Mr. Richard Jon Barry, also known as Rick, served as Independent Director at Cassava Sciences, Inc. since June 11, 2021, until July 17, 2024 and serves as its Executive Chairman of the Board since July 17,...


리더십 팀

이름위치테뉴어보상소유권
Richard Barry
CEO, President & Directorless than a yearUS$546.16k0.98%
$ 2.0m
Eric Schoen
Chief Financial Officer6.1yrsUS$2.99m0.048%
$ 100.1k
R. Cook
Senior VP2.1yrsUS$1.27m0%
$ 0
James Kupiec
Chief Medical Officer3.8yrsUS$2.97m0.0083%
$ 17.2k
George Thornton
Senior Vice President of Technologyno data데이터 없음데이터 없음
Michael Zamloot
Senior Vice President of Technical Operationsno data데이터 없음데이터 없음
Michael Marsman
Senior Vice President of Regulatory Affairs2yrs데이터 없음데이터 없음
Lindsay Burns
Senior Vice President of Neuroscience4.6yrs데이터 없음데이터 없음
Freda Nassif
Chief Commercial Officerno data데이터 없음데이터 없음
Jaren Landen
Chief Clinical Development Officerno data데이터 없음데이터 없음

2.0yrs

평균 재임 기간

62.5yo

평균 연령

경험이 풍부한 관리: SAVA 의 관리팀은 경험 ( 2 년 평균 재직 기간)으로 간주됩니다.


이사회 구성원

이름위치테뉴어보상소유권
Richard Barry
CEO, President & Director3.4yrsUS$546.16k0.98%
$ 2.0m
Patrick Scannon
Independent Director16.9yrsUS$438.42k0.0025%
$ 5.1k
Michael O'Donnell
Independent Director26.4yrsUS$438.42k0.017%
$ 35.4k
Grant Schoenhard
Member of Scientific Advisory Board10.1yrsUS$558.31k데이터 없음
Robert Gussin
Independent Director21.7yrsUS$546.16k0.026%
$ 54.7k
Claude Nicaise
Independent Chairmanless than a yearUS$474.50k0%
$ 0
Robert Anderson
Independent Directorless than a yearUS$474.50k0%
$ 0
Pierre Gravier
Independent Directorless than a yearUS$474.50k0%
$ 0

6.8yrs

평균 재임 기간

68.5yo

평균 연령

경험이 풍부한 이사회: SAVA 의 이사회경험(평균 재직 기간 6.8 년)으로 간주됩니다.